GlassScriptPhysician profile
Justin Weiner
NPI 1356501894
$16,669.88
in general payments reported to CMS, 2019-2025
36 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,922 · 2020: $1,953 · 2021: $2,924 · 2022: $4,053 · 2023: $1,903 · 2024: $550 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Consulting Fee: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.12 |
| Consulting Fee | $2,108.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,713.61 | 2019-2024 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $3,022.38 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,625.26 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,200.13 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $913.46 | 2019-2023 | Dupixent |
| Mylan Specialty L.P. | $796.43 | 2019-2023 | Yupelri |
| Insmed, INC. | $567.80 | 2019-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $559.95 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $504.97 | 2021-2023 | Tezspire |
| Harmony Biosciences LLC | $447.00 | 2020-2023 | Wakix |
| Sunovion Pharmaceuticals INC. | $355.03 | 2019-2020 | |
| Philips North America LLC | $338.43 | 2019-2023 | |
| Electromed, INC. | $319.37 | 2019-2023 | Smartvest |
| Eisai INC. | $294.15 | 2020-2022 | |
| Advanced Respiratory, INC | $260.21 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $251.27 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $190.86 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $187.51 | 2019-2023 | Belsomra, Steglatro |
| Mallinckrodt Hospital Products INC. | $186.44 | 2021-2022 | |
| Olympus America INC. | $125.00 | 2022 | |
| Baxter Healthcare | $97.91 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $85.34 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.06 | 2020 | |
| Circassia INC. | $72.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.41 | 2021-2022 | |
| Axsome Therapeutics, INC. | $50.72 | 2024 | Sunosi |
| Grifols USA, LLC | $49.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.21 | 2020-2023 | |
| Shire North American Group INC | $40.32 | 2019 | |
| Medtronic USA, INC. | $36.43 | 2019 | |
| Apria Healthcare LLC | $33.62 | 2021 | |
| Pfizer INC. | $28.49 | 2020-2022 | |
| Phadia US INC. | $21.24 | 2019 | |
| Optinose US, INC. | $17.26 | 2025 | |
| Foundation Medicine, INC. | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.